TNXP Tonix Pharmaceuticals Holding Corp.

2.27
-0.11  -5%
Previous Close 2.38
Open 2.35
Price To Book 0.58
Market Cap 13807849
Shares 6,089,728
Volume 758,643
Short Ratio
Av. Daily Volume 1,854,244

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial halted due to insufficient efficacy - July 27, 2018.
TNX-102 SL (Tonmya)
Post-traumatic stress disorder (PTSD)
Phase 2 data released February 2016 did not meet primary endpoint
TNX-201
Episodic tension-type headache
Phase 3 data September 6, 2016 did not meet primary endpoint - program discontinued. However company noted April 4, 2019 intention to initiate a Phase 3 trial.
TNX-102 SL
Fibromyalgia
New Phase 3 trial initiation announced March 11, 2019 with data due 1H 2020.
Tonmya
Post-traumatic stress disorder (PTSD)

Latest News

  1. Tonix Pharmaceuticals Announces that Breakthrough Therapy Designation Remains in Effect for Tonmya® for the Treatment of Posttraumatic Stress Disorder
  2. Tonix Pharmaceuticals R&D pact with U.S. Army to be terminated 'without cause'
  3. TNXP: Phase 3 Trial of TNX-102 SL in PTSD Underway…
  4. Four Healthcare Stocks Heating Up on Thursday
  5. What's Driving The Rally In Nanocap Biotech Tonix Pharma?
  6. Tonix Pharmaceuticals Plans to Expand TNX-102 SL Phase 3 Program Beyond PTSD to Include Fibromyalgia
  7. Tonix Pharmaceuticals to Present at Upcoming Investor Conferences
  8. Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights
  9. Tonix Pharmaceuticals to Participate at Upcoming Investor Conferences
  10. Four Healthcare Stocks Making Moves on Monday
  11. Tonix Pharmaceuticals Enrolls First Participant in the “RECOVERY” Study -- a New Phase 3 Trial of Tonmya® for the Treatment of Posttraumatic Stress Disorder
  12. Four Healthcare Stocks Surpassing Investor Expectations
  13. Tonix Pharmaceuticals Announces New European Use Patent for TNX-601
  14. Tonix Pharmaceuticals Provides Update on Tonmya® for the Treatment of Posttraumatic Stress Disorder
  15. Tonix Pharmaceuticals Announces Share Repurchase Program
  16. Tonix Pharmaceuticals Announces New Board Member, James Treco
  17. How Many Insiders Bought Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares?
  18. Tonix Pharmaceuticals to Present at BIO CEO & Investor Conference
  19. TNXP: Additional Details Revealed for Phase 3 Trial of TNX-102 SL in PTSD Starting in 1Q19…
  20. Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion